Authors

  • Ernesto L Mola
  • José A Buxadó
  • Luis Herrera

DOI:

https://doi.org/10.5912/jcb363

Keywords:

Cuba, Biotechnology, re-profiling, diabetes, ulcers, therapeutic

Abstract

This article deals with repurposing of the epidermal growth factor (EGF) to the treatment of diabetic foot ulcers (DFU) grades III and IV, according to the Wagner scale. The design of a repurposing commercial strategy is described in this document as a contribution to a body of knowledge with high uncertainty and lack of methodology for decision-makers. An analysis of the potential market suggested a significant impact of the product Heberprot-P® on costs associated to DFU treatment. Unexpected findings, obtained from a study of the competence, are reported here. The feasibility of a repurposing strategy containing short-, medium- and long-term action plans, without mutual interferences, and adopting strategic intent, strategic assessment and strategic choice as fundamental concepts is demonstrated in this work.